- Home
- LUMO
LUMO
Lumos Pharma Inc.
as 12-18-2024 1:39pm EST
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 37.4M | IPO Year: | N/A |
| Target Price: | $9.38 | AVG Volume (30 days): | 133.0K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.37 - $4.58 | Next Earning Date: | 11-07-2024 |
| Revenue: | $2,205,000 | Revenue Growth: | 26.94% |
| Revenue Growth (this year): | 184.11% | Revenue Growth (next year): | -85.12% |
Latest Lumos Pharma Inc. News
LUMO Breaking Stock News: Dive into LUMO Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
GlobeNewswire
a month ago
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
GlobeNewswire
2 months ago
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
Simply Wall St.
2 months ago
Discover Smart Share Global Among 2 Other Prominent US Penny Stocks
GlobeNewswire
2 months ago
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
GuruFocus.com
2 months ago
Lumos Pharma Inc (LUMO) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Prudence
GlobeNewswire
3 months ago
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
GlobeNewswire
3 months ago
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
Compare LUMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LUMO Lumos Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.